Justin Cohen is a remarkable young researcher, living with FSHD, and efforting to find a cure for the disease. The Carrino Foundation is proud to make his work possible. Here is Justin’s story, in his own words.
Expressing his hardships and triumphs while battling facioscapulohumeral muscular dystrophy, Bonita eighth-grader Sam Ray is one of the winners of the national Scholastic’s annual essay contest.The annual essay, “Breaking Barriers: In Sports, In Life,” was created by Scholastic and Major Baseball League in honor of Jackie Robinson, to inspire students by Robinson’s perseverance and to teach them how to use the same values he did to overcome hardships within their lives.
There are approximately 15 steps that Chris Carrino will need to navigate in order to reach his broadcast position inside Wells Fargo Center. It may not seem all that daunting, but a small flight of stairs is physically challenging and potentially dangerous for someone living with muscular dystrophy.
Be sure to mark your calendars now! Our ninth annual dinner dance will take place on Thursday, July 18, 2019, at Russo’s on the Bay in Howard Beach, NY. Details and ticket information will be available soon. Hope to see you there!
Facio Therapies announced today that it has selected its first series of potential FSHD drug development candidates. This series comprises several families of small-molecule compounds that are associated with a narrowly defined target class. Neither the compound families nor the target class have ever been linked to FSHD in the scientific literature.
Article originally appeared on sciencedaily.com, November 7, 2017. In a recent paper published in the journal Skeletal Muscle, a Saint Louis University researcher reports success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized by progressive muscle degeneration. Francis M. Sverdrup, Ph.D., research fellow in the …
Read more “FSHD NEWS: New drug targets for a form of muscular dystrophy”
Article originally appeared on musculardystrophynews.com, October 10, 2017. Resolaris (ATYR1940) improved the muscle strength of nearly two-thirds of adolescents and young adults with early-onset facioscapulohumeral muscular dystrophy (FSHD), according to final results of a Phase 1/2 clinical trial. The therapy’s maker, aTyr Pharma, presented the findings at the 22nd International Annual Congress of the World Muscle Society (WMS) in Saint Malo, France, according to a press release. The …
Bruce Beck of NBC 4 provides coverage of the C2C4FSHD bike tour.
Frank Carbone’s energy is infectious. Starting in Seattle and for the better part of two months, he led a group of cyclists across the country. CBS2’s Steve Overmyer caught up with him during a two-minute pit stop in Fort Lee before entering their final leg through New York City. “We’re home!” Carbone said. “Fifty-four days on the road!”
A 4,200-mile journey through 15 states that began in Seattle in May came to an end in Brooklyn Wednesday afternoon, as cyclists pedaled their way to the Barclays Center and celebrated the funding and awareness they raised for facioscapulohumeral muscular dystrophy.